PT  - JOURNAL ARTICLE
AU  - Shuang Ren
AU  - Juan Zeng
AU  - Ye Mei
AU  - John Z. H. Zhang
AU  - S. Frank Yan
AU  - Jian Fei
AU  - Li Chen
TI  - Discovery and Characterization of Novel, Potent, and Selective Cytochrome P450 2J2 Inhibitors
AID  - 10.1124/dmd.112.048264
DP  - 2013 Jan 01
TA  - Drug Metabolism and Disposition
PG  - 60--71
VI  - 41
IP  - 1
4099  - http://dmd.aspetjournals.org/content/41/1/60.short
4100  - http://dmd.aspetjournals.org/content/41/1/60.full
SO  - Drug Metab Dispos2013 Jan 01; 41
AB  - Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in the intestine suggest its potentially indispensable role in first-pass intestinal metabolism and involvement in drug-drug interaction. To fully characterize its role in drug metabolism, selective and potent inhibitors of CYP2J2 are necessary tools. In the current study, 69 known drugs were screened for the inhibition of CYP2J2, and we discovered a number of marketed drugs as potent and selective CYP2J2 inhibitors. In particular, telmisartan and flunarizine have CYP2J2 inhibition IC50 values of 0.42 μM and 0.94 μM, respectively, which are at least 10-fold more selective against all other major metabolizing CYPs; moreover, they are not substrates of CYP2J2 and show no time-dependent inhibition toward this CYP. The results of enzyme kinetics studies, supported by molecular modeling, have also elucidated that telmisartan is a mixed-type inhibitor, and flunarizine competitively inhibits CYP2J2. The Ki for telmisartan is 0.19 μM, with an α value, an indicator of the type of inhibition mechanism, of 2.80, and flunarizine has a Ki value of 0.13 μM. These newly discovered CYP2J2 inhibitors can be potentially used as a tool to study CYP2J2 in drug metabolism and interaction in a clinical setting.